Biotech News
InflaRx Announces November Investor Events
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November.
Related news
IFRXInflarx NV2026-11-03 12:00 EST
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
IFRXInflarx NV2026-10-22 16:00 EST
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
CMPXCompass Therapeutics2026-11-02 14:00 EST
Compass Therapeutics to Participate in Upcoming November Investor Events
SABSSAB Biotherapeutics2026-10-29 12:30 EST
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
CRVSCorvus Pharmaceuticals2026-10-29 12:00 EST
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
AVTXAvalo Therapeutics2026-11-02 21:00 EST
Avalo Therapeutics to Participate in Upcoming Investor Conferences
LEGNLegend Biotech Corporation2026-10-27 12:00 EST
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
IMVTImmunovant2026-10-21 11:00 EST
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
BNTXBioNTech2026-10-20 10:45 EST
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
Inflarx NV
Complement-Targeted Immunology InflaRx develops anti-inflammatory therapies that inhibit the complement C5a pathway. Its portfolio includes an oral C5a receptor inhibitor and an antibody against C5a. Izicopan Izicopan is an oral C5aR inhibitor designed for differentiated chemistry, metabolic properties and safety. Phase 2a results in...
Recent company news
IFRXInflarx NV2026-11-03 12:00 EST
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
IFRXInflarx NV2026-10-27 11:30 EST
InflaRx Announces November Investor Events
IFRXInflarx NV2026-10-22 16:00 EST
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
IFRXInflarx NV2026-10-02 11:30 EST
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
IFRXInflarx NV2026-10-01 11:30 EST
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Stock data
- Close
- 1.36 USD
- Market cap
- 319.63M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States